

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**RemeGen Co., Ltd.\***

**榮昌生物製藥(煙台)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9995)**

## **CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE**

The board (the “**Board**”) of directors (the “**Directors**”) of RemeGen Co., Ltd.\* 榮昌生物製藥(煙台)股份有限公司 (the “**Company**”) hereby announces the following changes in the composition of the nomination committee of the Board (the “**Nomination Committee**”) with effect from May 26, 2025:

- (i) Mr. Wang Weidong, the chairman of the Board and an executive Director, will cease to be a member of the Nomination Committee; and
- (ii) Dr. Su Xiaodi, a non-executive Director, has been appointed as a member of the Nomination Committee.

Following the above changes, the Nomination Committee will comprise three members, namely Mr. Huang Guobin (chairman), Mr. Hao Xianjing, and Dr. Su Xiaodi.

The above changes were made in response to the amended Corporate Governance Code and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited which will come into effect on July 1, 2025. Good corporate governance plays a significant role in the overall performance of the Company and the Board believes that the implementation of such changes could strengthen the effectiveness and diversity of the Board and further enhance good corporate governance practice of the Company as a whole.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Wang Weidong for his valuable contributions to the Company during his tenure as a member of the Nomination Committee, and to extend its warm welcome to Dr. Su Xiaodi in her new role in the Nomination Committee.

By order of the Board  
**RemeGen Co., Ltd.\***  
**Mr. Wang Weidong**  
*Chairman and executive Director*

Yantai, The People's Republic of China  
May 26, 2025

*As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as independent non-executive Directors.*

\* *For identification purpose only*